Neoadjuvant treatment of HER2-positive breast cancer: Has the era of antibody-drug conjugates arrived?
1. 系统已在2025-04-17 14:48:13对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
A Papakonstantinou, T Foukakis
Annals of Oncology, 2025
annalsofoncology.org
HER2-positive breast cancer is the epitome of the success of Antibody-Drug Conjugates (ADCs) in oncology, with several molecules demonstrating activity and two agends approved, trastuzumab emtansine (T-DM1) and more recently trastuzumab deruxtecan (T-DXd). The quest for the optimal antibody-linker-payload combination and the position of all agents in the treatment arsenal is still ongoing. In the current issue of Annals of Oncology, Li et al present data for a novel trastzumab-based ADC with a cleavable linker and a …
